SAGE Therapeutics’ valuation
SAGE Therapeutics (SAGE), a clinical research–based biopharmaceutical company, develops drugs for the treatment of life-threatening central nervous system disorders such as Parkinson’s disease and postpartum depression.
The chart above shows analysts’ recommendations for SAGE Therapeutics over the last 12 months. The company has not generated revenue from product sales since its inception, and it doesn’t expect to generate any revenue from product sales in the second quarter.
Analysts expect the company to see net income of -$85.7 million in the second quarter and net income of -$381.7 million in 2018. They expect the company’s revenue flow to begin in the fourth quarter, when its revenue is expected to be ~$4.3 million.
SAGE Therapeutics’ stock price has risen nearly 111.5% in the last 12 months, while analysts estimate that the stock has the potential to return 26.6% over the next 12 months. Analysts’ recommendations show a 12-month target price of $208.64 per share compared to its price of $164.84 on June 14.
As of June 15, 14 analysts are tracking SAGE Therapeutics stock. Of these, six analysts have recommended “strong buys,” while eight have recommended “buys.” The consensus rating on SAGE Therapeutics stock is 1.57, which represents a “buy” for both momentum investors and long-term investors.
The First Trust NASDAQ Pharmaceuticals ETF (FTXH) holds 4.3% of its total investments in SAGE Therapeutics, 7.4% in Johnson & Johnson (JNJ), 4.4% in Eli Lilly and Company (LLY), and 6.3% in Bristol-Myers Squibb (BMY).
Check out all the data we have added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend info. Take a look!